This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.
This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2018 American Society of Hematology (ASH) Annual Meeting including the use of Imbruvica in front-line chronic lymphocytic leukemia (CLL), FLT3 inhibitors in acute myeloid leukemia (AML) and CAR-T therapy in CLL, multiple myeloma and other indications. Survey questions and additional resources are listed further below.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.